Three‐year outcomes with brentuximab vedotin plus bendamustine as first salvage therapy in relapsed or refractory Hodgkin lymphoma

Ann S. LaCasce; R. Gregory Bociek; Ahmed Sawas; Paolo Caimi; Edward Agura; Jeffrey Matous; Stephen M. Ansell; Howland E. Crosswell; Miguel Islas-Ohlmayer; Caroline Behler; Eric Cheung; Andres Forero-Torres; Julie Vose; Owen A. O’Connor; Neil Josephson; Yinghui Wang; Ranjana Advani

doi:10.1111/BJH.16499

Three‐year outcomes with brentuximab vedotin plus bendamustine as first salvage therapy in relapsed or refractory Hodgkin lymphoma

Ann S. LaCasce
, R. Gregory Bociek
, Ahmed Sawas
, Paolo Caimi
, Edward Agura
, Jeffrey Matous
, Stephen M. Ansell
, Howland E. Crosswell
, Miguel Islas-Ohlmayer
, Caroline Behler
, Eric Cheung
, Andres Forero-Torres
, Julie Vose
, Owen A. O’Connor
, Neil Josephson
, Yinghui Wang
, Ranjana Advani

Harvard University
University of Nebraska Medical Center
Columbia University Medical Center
University Hospitals of Cleveland
Charles A. Sammons Cancer Center Dallas TX USA
Colorado Blood Cancer Institute Denver CO USA
Mayo Clinic
Saint Francis University
Jewish Hospital
Pacific Hematology Oncology Associates San Francisco CA USA
The Oncology Institute of Hope & Innovation Whittier CA USA
University of Alabama at Birmingham
Seattle Genetics
Stanford University

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	British Journal of Haematology
Volume	189
Issue number	3
DOIs	https://doi.org/10.1111/BJH.16499
State	Published - Feb 12 2020
Externally published	Yes

Disciplines

Medicine and Health Sciences
Oncology
Internal Medicine

Access to Document

10.1111/BJH.16499License: Unspecified

Cite this

LaCasce, A. S., Bociek, R. G., Sawas, A., Caimi, P., Agura, E., Matous, J., Ansell, S. M., Crosswell, H. E., Islas-Ohlmayer, M., Behler, C., Cheung, E., Forero-Torres, A., Vose, J., O’Connor, O. A., Josephson, N., Wang, Y., & Advani, R. (2020). Three‐year outcomes with brentuximab vedotin plus bendamustine as first salvage therapy in relapsed or refractory Hodgkin lymphoma. British Journal of Haematology, 189(3). https://doi.org/10.1111/BJH.16499

LaCasce, AS, Bociek, RG, Sawas, A, Caimi, P, Agura, E, Matous, J, Ansell, SM, Crosswell, HE, Islas-Ohlmayer, M, Behler, C, Cheung, E, Forero-Torres, A, Vose, J, O’Connor, OA, Josephson, N, Wang, Y & Advani, R 2020, 'Three‐year outcomes with brentuximab vedotin plus bendamustine as first salvage therapy in relapsed or refractory Hodgkin lymphoma', British Journal of Haematology, vol. 189, no. 3. https://doi.org/10.1111/BJH.16499

@article{1a7abd1e69d0488fbf155dcc76340743,

title = "Three‐year outcomes with brentuximab vedotin plus bendamustine as first salvage therapy in relapsed or refractory Hodgkin lymphoma",

author = "LaCasce, \{Ann S.\} and Bociek, \{R. Gregory\} and Ahmed Sawas and Paolo Caimi and Edward Agura and Jeffrey Matous and Ansell, \{Stephen M.\} and Crosswell, \{Howland E.\} and Miguel Islas-Ohlmayer and Caroline Behler and Eric Cheung and Andres Forero-Torres and Julie Vose and O{\textquoteright}Connor, \{Owen A.\} and Neil Josephson and Yinghui Wang and Ranjana Advani",

year = "2020",

month = feb,

day = "12",

doi = "10.1111/BJH.16499",

language = "American English",

volume = "189",

journal = "British Journal of Haematology",

number = "3",

}

TY - JOUR

T1 - Three‐year outcomes with brentuximab vedotin plus bendamustine as first salvage therapy in relapsed or refractory Hodgkin lymphoma

AU - LaCasce, Ann S.

AU - Bociek, R. Gregory

AU - Sawas, Ahmed

AU - Caimi, Paolo

AU - Agura, Edward

AU - Matous, Jeffrey

AU - Ansell, Stephen M.

AU - Crosswell, Howland E.

AU - Islas-Ohlmayer, Miguel

AU - Behler, Caroline

AU - Cheung, Eric

AU - Forero-Torres, Andres

AU - Vose, Julie

AU - O’Connor, Owen A.

AU - Josephson, Neil

AU - Wang, Yinghui

AU - Advani, Ranjana

PY - 2020/2/12

Y1 - 2020/2/12

UR - https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.16499

U2 - 10.1111/BJH.16499

DO - 10.1111/BJH.16499

M3 - Article

VL - 189

JO - British Journal of Haematology

JF - British Journal of Haematology

IS - 3

ER -

Three‐year outcomes with brentuximab vedotin plus bendamustine as first salvage therapy in relapsed or refractory Hodgkin lymphoma

Disciplines

Access to Document

Other files and links

Cite this